Central variant of posterior reversible encephalopathy syndrome in systemic lupus erythematosus: new associations?
Bag
A K
AK
Curé
J K
JK
Sullivan
J C
JC
Roberson
G H
GH
D018501:Antirheumatic Agents / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006886:Hydroxychloroquine / Q000009:adverse effects / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D008180:Lupus Erythematosus, Systemic / Q000150:complications* / Q000188:drug therapy; D015122:Mercaptopurine / Q000009:adverse effects / Q000627:therapeutic use; D054038:Posterior Leukoencephalopathy Syndrome / Q000209:etiology* / Q000503:physiopathology; D055815:Young Adult
D018501:Antirheumatic Agents; D007166:Immunosuppressive Agents; D006886:Hydroxychloroquine; D015122:Mercaptopurine